Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $5.5 million.

  • Mimedx's Other Non-Current Liabilities rose 8881.67% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 8881.67%. This contributed to the annual value of $7.4 million for FY2024, which is 23211.88% up from last year.
  • As of Q3 2025, Mimedx's Other Non-Current Liabilities stood at $5.5 million, which was up 8881.67% from $7.0 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Other Non-Current Liabilities ranged from a high of $7.5 million in Q1 2025 and a low of $2.2 million during Q4 2023
  • In the last 5 years, Mimedx's Other Non-Current Liabilities had a median value of $4.3 million in 2022 and averaged $4.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 5342.55% in 2023, then soared by 23211.88% in 2024.
  • Quarter analysis of 5 years shows Mimedx's Other Non-Current Liabilities stood at $4.9 million in 2021, then dropped by 1.97% to $4.8 million in 2022, then tumbled by 53.43% to $2.2 million in 2023, then surged by 232.12% to $7.4 million in 2024, then fell by 25.22% to $5.5 million in 2025.
  • Its Other Non-Current Liabilities was $5.5 million in Q3 2025, compared to $7.0 million in Q2 2025 and $7.5 million in Q1 2025.